Healthcare Business

Top Presentations to Look for at ASCO

It almost the end of May, and that means one thing for biotech investors. The king of biotech and pharma events is about to take place. The 2017 annual meeting ...
Read Full Story »

Can MEI Pharma Rise Nearly 300%?

MEI Pharma, Inc. (NASDAQ: MEIP) saw its shares make a solid gain on Thursday after the company received a crucial upgrade from Oppenheimer. Most analysts only issue price targets that ...
Read Full Story »

Big Pharma Has Big Catalysts Coming for the Rest of 2017

The big pharmaceutical stocks are one area that has done somewhat better this year. One major reason for that is the shrill rhetoric from politicians has quieted as the election ...
Read Full Story »

Short Sellers Raise the Stakes in Major Biotechs

The short interest data are out for the most recent settlement date, May 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Major Pharma Short Interest Surges

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

What to Expect From Eli Lilly at ASCO

In the coming weeks, biotech and pharma companies will descend on Chicago for one of the biggest conferences in 2017. The 2017 annual meeting of the American Society of Clinical ...
Read Full Story »

Why Inovio Pharmaceuticals May Be the Next Big Thing

Shares of Inovio Pharmaceuticals Inc. (NASDAQ: INO) saw a massive gain early on Wednesday after the company announced a critical update from its HIV vaccine. Specifically, the company said that ...
Read Full Story »

What Analysts Have to Say About Agilent Technologies After Earnings

After Agilent Technologies Inc. (NYSE: A) reported its fiscal second-quarter financial results late on Monday, investors were very happy with the beats on both the top and bottom lines. Analysts also ...
Read Full Story »

JPMorgan’s Favorite Biotechs to Buy With Massive Upside Potential

After a couple of down years in which the shrill political rhetoric over drug prices kept a pall over the industry, the biotechs are showing some signs of life. In ...
Read Full Story »

Why Endologix Shares Are Hitting a Multiyear Low

Endologix Inc. (NASDAQ: ELGX) saw its shares hit a multiyear low following a meeting with the U.S. Food and Drug Administration (FDA). After this meeting, the company provided an update ...
Read Full Story »

How ASCO Could Make or Break These 5 Cancer Drug Trials

We are now halfway through May, and that means one thing for biotech investors. The king of biotech and pharma events is about to take place. The 2017 annual meeting ...
Read Full Story »

Why This Humira Patent Loss Might Not Be What You Think

AbbVie Inc. (NYSE: ABBV) watched its shares slide on Wednesday following a ruling from the U.S. Patent and Trade Mark Office Trial and Appeals Board that found in favor of ...
Read Full Story »

Why Syndax Shares Are Rallying

Shares of Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) saw a huge gain on Wednesday after the firm gave an update on its non-small cell lung cancer (NSCLC) midstage trial. Specifically, the ...
Read Full Story »

Is Editas Facing a New Reality in CRISPR Land?

Editas Medicine Inc. (NASDAQ: EDIT) is one of the biotech and biohealth players that sits on the cusp of new technology and developments for the next major growth phase in ...
Read Full Story »

Why Akebia Shares Are Hitting New Highs

Akebia Therapeutics Inc. (NASDAQ: AKBA) saw its shares hit a new 52-week high in Tuesday’s session following a key licensing agreement with Vifor Pharma. Specifically this is an exclusive license ...
Read Full Story »